QIAGEN NV NEW YORK and HILDEN, Germany, June 21, 2016 /PRNewswire/ --
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration with Weill Cornell Medicine in a global study seeking insights on the prevalence of pathogens, including antimicrobial resistance, in urban environments. Starting today, researchers will simultaneously collect DNA and RNA samples from high-traffic areas in subway systems, buses and parks in 54 cities around the world - expanding on a metagenomic portrait of microbes in the New York City subways published in 2015. The project will use QIAGEN sample technologies and library preparation workflows to extract and prepare genomic materials for analysis.
"Mapping the unseen genomes and epigenomes of cities across six continents is an exciting effort that illustrates the potential for metagenomics to create new insights into interactions among humans, our environment and the microbes that have an impact on our health," said Colin Baron, Senior Director and Head of QIAGEN's Product Management NGS Life Sciences. "QIAGEN is pleased that the scientific leaders in this international collaboration have selected our MO BIO PowerSoil(R) sample technology kits for sample extraction and QIAseq FX DNA library preparation kits to enable reliable next-generation sequencing."
Click here [https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID=%7b5D2BB776-F232-43F1-A44A-E40151C1AEDF%7d&lang=en ] for the full press release
Pathomap / Microbiome / Gates Foundation / Olympics / MetaSUB / Dr. Christopher E. Mason
Public Relations:
Dr. Thomas Theuringer
Senior Director Public Relations
+49-2103-29-11826
Email: pr@qiagen.com
www.twitter.com/qiagen [http://www.twitter.com/qiagen ]
https://www.facebook.com/QIAGEN
pr.qiagen.com
Investor Relations:
John Gilardi
Vice President Corporate Communications and Investor Relations
+49-2103-29-11711
Email: ir@qiagen.com
ir.qiagen.com
SOURCE QIAGEN N.V.
